Standard for Exchange of Nonclinical Data (SEND) Latest Registration
CLEVELAND [December 17] /PRNewswire/ — DATATRAK International, Inc. (OTCQX: DTRK), a leader in developing cloud-based, unified eClinical® technologies and delivering related services for the clinical trials industry, today announced the addition of the CDISC Standard for Exchange of Nonclinical Data (SEND) Registered Solutions Provider to existing CDISC registrations. DATATRAK completed the SEND registration in preparation for supporting data collection and FDA submissions for preclinical studies.
“Standards expertise becomes even more important with the upcoming industry mandated CDISC-formatted submissions deadline,” stated Laurence P. Birch, DATATRAK’s Chairman of the Board and CEO. “Our commitment to standards and our customers is exemplified through our continued effort to expand our CDISC capabilities. Our new SEND certification is one more value-added service we can provide our clients in the acceleration of their drug and device approvals – starting with their preclinical trials.”
DATATRAK is a leader in driving CDISC standards compliance with seven of the standards supported – CDASH, Define-XML, LAB, ODM, SDTM, SEND and Terminology. For additional information on CDISC and Registered Solution Provider registrations, please see www.cdisc.org.
Join DATATRAK Thought Leaders:
Tweet: #DATATRAK Registered Solutions Provider for SEND. http://bit.ly/1hfD0Vv
DATATRAK International is a worldwide technology and services company delivering unified eClinical® solutions and related services for the clinical trials industry. DATATRAK built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery via DATATRAK’s Clinical and Consulting Services group. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. The DATATRAK ONE™ software solution, deployed worldwide through an ASP or Enterprise Transfer offering, supports Phase I – Phase IV drug and device studies in multiple languages throughout the world. DATATRAK has offices located in Cleveland, Ohio; Bryan, Texas; and Cary (RTP), North Carolina. For more information, visit http://www.datatrak.com.
Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management’s expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company’s report filed with the OTCQX Market on November 14, 2013 announcing its results for the third quarter of 2013. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.
Lisa Pahl, Director Marketing, DATATRAK International, Inc., +1-979-393-9025